We found no clear evidence that paroxetine was more or less effective compared with other antidepressants at increasing response to treatment at acute ( six to 12 weeks ) , early ( one to four weeks ) , or longer term follow-up ( four to six months ) .
Paroxetine was associated with a lower rate of adverse events than amitriptyline , imipramine and older ADs as a class , but was less well tolerated than agomelatine and hypericum .
Some possibly clinical ly meaningful differences between paroxetine and other ADs exist , but no definitive conclusions can be drawn from these findings .
In terms of early response to treatment ( one to four weeks ) there was moderate quality of evidence that mirtazapine was better than paroxetine and that paroxetine was better than reboxetine .
However there was no clear evidence that paroxetine was better or worse compared with other antidepressants at increasing response to treatment at any time point .
BACKGROUND Paroxetine is the most potent inhibitor of the reuptake of serotonin of all selective serotonin reuptake inhibitors ( SSRIs ) and has been studied in many r and omised controlled trials ( RCTs ) .
However , these comparative studies provided contrasting findings and systematic review s of RCTs have always considered the SSRIs as a group , and evidence applicable to this group of drugs might not be applicable to paroxetine alone .
The present systematic review assessed the efficacy and tolerability profile of paroxetine in comparison with tricyclics ( TCAs ) , SSRIs and newer or non-conventional agents .
OBJECTIVES 1 .
To determine the efficacy of paroxetine in comparison with other anti-depressive agents in alleviating the acute symptoms of Major Depressive Disorder.2  .
To review acceptability of treatment with paroxetine in comparison with other anti-depressive agents.3 .
To investigate the adverse effects of paroxetine in comparison with other anti-depressive agents .
Sexual Function during Bupropion or Paroxetine Treatment of Major Depressive Disorder
Objective : The primary objective was to evaluate sexual function ( SF ) separately in men and women with major depressive disorder ( MDD ) before and during treatment with bupropion sustained release ( SR ) or paroxetine .  The secondary objectives involved a comparative evaluation of the Sex Effects Scale ( Sex FX ) and the Investigator-Rated Sexual Desire and Functioning Scale ( IRSD-F ) , as well as a comparison of antidepressant outcomes and an examination of the relation between level of depression and SF over time . Method : There were 141 patients ( 68 women and 73 men ) who met DSM-IV criteria for a current major depressive episode . They were r and omly assigned to receive bupropion SR ( 150 to 300 mg daily ) or paroxetine ( 20 to 40 mg daily ) under double-blind trial conditions . Patients were assessed at baseline and at 2 , 4 , 6 , and 8 weeks with the 17-item Hamilton Depression Rating Scale ( HDRS17 ) , Sex FX , and IRSD-F. Results : Prior to treatment , women reported significantly lower SF on both the Sex FX and IRSD-F scales , compared with men . During treatment , there were no significant drug differences on measures of SF over time for women ; however , men who were treated with paroxetine reported a worsening of SF , whereas bupropion SR did not significantly alter SF . Both bupropion SR and paroxetine produced clinical ly and statistically significant reductions in HDRS17 scores as well as comparable rates of response and remission . There was a statistically significant correlation between the 2 measures of SF at all visits . There was also a significant inverse relation between depression and SF in women , but not in men , irrespective of drug . Conclusion : According to the Sex FX scale , a significant difference in antidepressant-related sexual dysfunction was detected in men , but not women , during treatment with bupropion SR or paroxetine
We found no clear evidence that paroxetine was more or less effective compared with other antidepressants at increasing response to treatment at acute ( six to 12 weeks ) , early ( one to four weeks ) , or longer term follow-up ( four to six months ) .
Paroxetine was associated with a lower rate of adverse events than amitriptyline , imipramine and older ADs as a class , but was less well tolerated than agomelatine and hypericum .
Some possibly clinical ly meaningful differences between paroxetine and other ADs exist , but no definitive conclusions can be drawn from these findings .
In terms of early response to treatment ( one to four weeks ) there was moderate quality of evidence that mirtazapine was better than paroxetine and that paroxetine was better than reboxetine .
However there was no clear evidence that paroxetine was better or worse compared with other antidepressants at increasing response to treatment at any time point .
BACKGROUND Paroxetine is the most potent inhibitor of the reuptake of serotonin of all selective serotonin reuptake inhibitors ( SSRIs ) and has been studied in many r and omised controlled trials ( RCTs ) .
However , these comparative studies provided contrasting findings and systematic review s of RCTs have always considered the SSRIs as a group , and evidence applicable to this group of drugs might not be applicable to paroxetine alone .
The present systematic review assessed the efficacy and tolerability profile of paroxetine in comparison with tricyclics ( TCAs ) , SSRIs and newer or non-conventional agents .
OBJECTIVES 1 .
To determine the efficacy of paroxetine in comparison with other anti-depressive agents in alleviating the acute symptoms of Major Depressive Disorder.2  .
To review acceptability of treatment with paroxetine in comparison with other anti-depressive agents.3 .
To investigate the adverse effects of paroxetine in comparison with other anti-depressive agents .